Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026)
Verano Holdings (VRNO) reported Total Non-Current Liabilities of $902.9 million for Q1 2026, up 5.02% year-over-year from $859.7 million in Q1 2025, and little changed quarter-over-quarter from $899.0 million in Q4 2025.
Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Total Non-Current Liabilities data on file, last reported at $902.9 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $902.9 million, up 5.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $902.9 million (up 5.02% YoY), and the FY2025 annual result was $899.0 million, up 7.0% from the prior year.
- Total Non-Current Liabilities steadied at $902.9 million in Q1 2026 per VRNO's latest filing, from $899.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $902.9 million in Q1 2026 and troughed at $469.5 million in Q2 2022.
- A 5-year average of $736.3 million and a median of $680.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 43.17% in 2023, then slipped 4.02% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $667.9 million in 2022, then decreased by 0.21% to $666.5 million in 2023, then grew by 26.06% to $840.2 million in 2024, then grew by 7.0% to $899.0 million in 2025, then increased by 0.44% to $902.9 million in 2026.
- Business Quant data shows VRNO's Total Non-Current Liabilities at $902.9 million in Q1 2026, $899.0 million in Q4 2025, and $897.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Verano Holdings | - | - | 98.98 Mn | 902.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 902.87 Mn |
| Dec 31, 2025 | 898.95 Mn |
| Sep 30, 2025 | 897.85 Mn |
| Jun 30, 2025 | 868.42 Mn |
| Mar 31, 2025 | 859.73 Mn |
| Dec 31, 2024 | 840.17 Mn |
| Sep 30, 2024 | 661.59 Mn |
| Jun 30, 2024 | 657.07 Mn |
| Mar 31, 2024 | 661.13 Mn |
| Dec 31, 2023 | 666.48 Mn |
| Sep 30, 2023 | 689.32 Mn |
| Jun 30, 2023 | 672.14 Mn |
| Mar 31, 2023 | 669.11 Mn |
| Dec 31, 2022 | 667.86 Mn |
| Sep 30, 2022 | 698.54 Mn |
| Jun 30, 2022 | 469.47 Mn |
| Dec 31, 2021 | 596.33 Mn |